DT07 Rec'd PCT 0 0 2 MAR 2005 PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/521,675 **TRANSMITTAL** Filing Date 01/18/2005 **FORM** First Named Inventor Won II YOO Art Unit (to be used for all correspondence after initial filing) N/A **Examiner Name** N/A Attorney Docket Number 59520-00009 Total Number of Pages in This Submission

		ENCLOSURES (Check all that apply)		
	Fee Transmittal Form	Drawing(s)	After Allowance communication to Technology Center (TC)		
	Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts	Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks Copies of the references are not counted in the	Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): IDS References C1-C5 and Return Receipt Postcard		
	under 37 CFR 1.52 or 1.53				
	SIGNA	TURE OF APPLICANT, ATTORNEY, C	R AGENT		
Firm or Individ	Joseph Hyosuk Kim Reg. No. 41,425 JHK Law				
Signat	ure Soul H	youle for			
Date	Eebruary 26, 2005				
CERTIFICATE OF TRANSMISSION/MAILING					
l hereb	by certify that this correspondence is lent postage as first class mail in an er	peing facsimile transmitted to the USPTO or depos avelope addressed to: Commissioner for Patents, F	ited with the United States Postal Service with P.O. Box 1450, Alexandria, VA 22313-1450 on		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Date

Februay 26, 2005.

Typed or printed name

Signature

Harry Sung Lee



PATENT

I hereby certify that on February 26, 2005, which is the date I am signing this certificate, I am depositing this correspondence and all identified attachments with the U.S. Postal Service, Express Mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Serial No.:10/521,675 Filed: 1/18/2005

Applicant: Won Il Yoo et al.

Title: PROTEIN FOR DIAGNOSING
DIABETIC RETINOPATHY

Examiner: N/A
Art Unit: N/A

Attorney Docket No.: 59520-00009

Hanlee

Harry Lee

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached Form PTO/SB/08B (substitute for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

English Language Documents:

1. Genbank Accession No. P01876 'Ig alpha-1 chain C region' 1 February 1991 (01.02.1991)

Application No. 10/521,675

59520-00009

- 2. Genbank Accession No. AJ294729 'Homo sapiens partial mRNA for immunoglobulin heavy chain constant region alpha 1 (IGHA1 gene)' 9 February 2001 (09.02.2001)
- 3. LEE E.Y. et al. 'Immunoglobulin A nephropathy in patients with non-insulin dependent diabetes mellitus' In: J Korean Med Sci, 1999, Vol. 14, pp582-585
- PEEBLES R.S. Jr. et al. 'IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays' In: J Immunol Methods, 1995, Vol.179, pp77-86
- 5. STOLWIJK T.R. et al. 'Analysis of tear fluid proteins in insulin-dependent diabetes mellitus' In: Acta Ophthalmol, 1994, Vol.72(3), pp357-362

It is respectfully requested that the Examiner indicate consideration of the cited references by returning the copy of the attached Form PTO/SB/08B with initials or other appropriate marks, and that the references be made of record as cited references in the application.

Respectfully submitted,

February 26, 2005

Date

løseph Hyosuk Kim, I

Reg. No. 41,425

Attorney for Applicants

JHK Law

P.O. Box 1078

La Canada, CA 91012-1078 Telephone: (818) 249-8177

Facsimile: (818) 249-8277

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08B (08-03)

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

The same of the sa	e for form 1449/PTO	-		I	Complete if Known	$\overline{}$
DE	10 10 10 11 1445 11 10			Application Number	10/521,675	
INF	DRMATION	DIS	CLOSURE	Filing Date	1/18/2005	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Won II Yoo	
	(Use as many she			Art Unit	N/A	
	(Use as many sne	eis as n	ecessary)	Examiner Name	N/A	
Sheet	1	of	1	Attorney Docket Number	59520-00009	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	1. Genbank Accession No. P01876 'lg alpha-1 chain C region' 1 February 1991 (01.02.1991)	
	C2	2. Genbank Accession No. AJ294729 'Homo sapiens partial mRNA for immunoglobulin heavy chain constant region alpha 1 (IGHA1 gene)' 9 February 2001 (09.02.2001)	
	С3	3. LEE E.Y. et al. 'Immunoglobulin A nephropathy in patients with non-insulin dependent diabetes mellitus' In: J Korean Med Sci, 1999, Vol. 14, pp582-585	
	C4	4. PEEBLES R.S. Jr. et al. 'IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays' In: J Immunol Methods, 1995, Vol.179, pp77-86	
	C5	5. STOLWIJK T.R. et al. 'Analysis of tear fluid proteins in insulin-dependent diabetes mellitus' In: Acta Ophthalmol, 1994, Vol.72(3), pp357-362	

Examiner	,	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.